cancer-vaccine

Twenty People, No Control Arm, and a Startup on the Side: Reading the Pancreatic Cancer Vaccine's Fine Print

Ninety percent of twenty volunteers made KRAS-specific T cells. None was shown to avoid cancer. Two of the investigators co-founded the company that licensed the shot from Johns Hopkins, which stands to collect royalties.